Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

muromonab-CD3

A murine IgG2a monoclonal antibody with immunosuppressive activity. Muromonab-CD3 binds to and inhibits CD3 on the surface of circulating T-lymphocytes; binding of muromonab-CD3 to CD3-positive T cells results in an early activation of this T cell subset, followed by cytokine release, and subsequently inhibition of T cell functions. This agent may cause the opsonization and elimination of CD3-positive T cells from the circulation by mononuclear phagocytes in the liver and spleen. CD3 is part of the functional T cell receptor (TCR) complex, which is necessary for antigen recognition by T cells, and is required for signal transduction.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Anti-CD3 monoclonal antibody OKT3
MOAB OKT3
monoclonal antibody OKT3
OKT3
US brand name:Orthoclone OKT3
Abbreviation:MOAB OKT3
IND number:2851
3546
3860
6883
NSC code:618843
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search